Screener
Gilead Sciences GILD Common Stock
Common Stock at other companies
Other financials
Where this comes from
Reported directly by Gilead Sciences in its filing.
Tagged under the XBRL concept us-gaap:CommonStockSharesAuthorized.
The source filing: Gilead Sciences’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:13 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000882095-26-000031
| (in millions, except per share amounts) | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Commitments and contingencies (Note 10) | ||
| Stockholders’ equity: | ||
| Preferred stock, par value $0.001 per share; 5 shares authorized; none outstanding | — | — |
| Common stock, par value $0.001 per share; 5,600 shares authorized; 1,241 shares issued and outstanding | 1 | 1 |
| Additional paid-in capital | 9,532 | 8,932 |
| Accumulated other comprehensive income | 95 | 39 |
| Retained earnings | 2,200 | 13,730 |
| Total Gilead stockholders’ equity | 11,829 | 22,703 |
Item 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FAQ
- What is Gilead Sciences's common stock?
- Gilead Sciences (GILD) reported common stock of 5.6B in Q2 2026.
- How has Gilead Sciences's common stock changed year-over-year?
- Gilead Sciences's common stock decreased by 0.0% year-over-year, from 5.6B to 5.6B.
- What is the long-term trend for Gilead Sciences's common stock?
- Over 5 years (2020 to 2025), Gilead Sciences's common stock has grown at a 461.9% compound annual growth rate (CAGR), from 1M to 5.6B.
- What does common stock mean?
- The par value of all common shares issued and outstanding, typically a nominal amount ($0.01 or $0.001 per share).
Ask your AI about Gilead Sciences's common stock.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude